Disease-specific survival for patients with multiple myeloma: Significant improvements over time in all age groups

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2850-2857

  Libby, Edward ^a,b   Garcia, David ^a   Quintana, Dulcinea ^c   Fekrazad, M Houman ^c,d   Bauman, Julie ^e   Ebaid, Ala ^c   Hromas, Robert ^f   Rabinowitz, Ian ^c   Wiggins, Charles ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

Clinical results; Myeloma; Prognostication

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CAUSE SPECIFIC SURVIVAL; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; TIME; ETHNOLOGY; HISTORY; INCIDENCE; MIDDLE AGED; MORTALITY; PROGNOSIS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SEER PROGRAM; UNITED STATES;

EID: 84907994923     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.897700     Document Type: Article

References (45)

1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685.
2. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-1999.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
5. Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2009;28:830-834.
6. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
7. Kumar SK, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre-and post-treatment options. Bone Marrow Transplant 2007;40:1115-1121.
8. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
9. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157.
10. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011;16:1600-1603.
11. Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40, 000 multiple myeloma patients. Int J Hematol 2012;95:64-70.
12. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prevent 1999; 8: 1117-1121.
13. Fritz A, Percy C, Jack A, et al., editors. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER ∗ Stat Database: Incidence-SEER 9 Registry Research Data, November 2010 Submission (1973-2008) Katrina Rita Population Adjustment-Linked To County Attributes-Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011 (updated 10/28/2011), based on the November 2010 submission. Available from: www.seer.cancer.gov
15. Surveillance, Epidemiology, and End Results (SEER) Program. SEER ∗ Stat Database: Mortality-All Causes-Of-Death, Aggregated With State, Total U.S. (1969-2008) Katrina Rita Population Adjustment, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released September 2011. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
16. Available from: www.seer.cancer.gov
17. Moriyama IM, Loy RM, Robb-Smith AHT. History of the statistical classification of diseases and causes of death. Rosenberg HM, Hoyert DL, editors. Hyattsville, MD: National Center for Health Statistics; 2011.
18. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cause of Death Recode 1969+ (xxx). Available from: www.seer. cancer.gov/codrecode/1969+-d09172004/index.html
19. Surveillance, Epidemiology, and End Results (SEER) Program. U.S. population data 1969-2008. Underlying census data provided by the U.S. Census Bureau www.census.gov).
20. Available from: www.seer.cancer.gov/popdata/download.html
21. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadephia, PA: Lippincott-Raven; 1998. pp 260-261.
22. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Statistical Notes. No 20. Hyattsville, MD: National Center for Health Statisics; January 2001.
23. Surveillance Research Program, National Cancer Institute. SEER ∗ Stat Software, Version 6.1.4. April 2005.
24. Kim HJFM, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.
25. Erratum in Stat Med 2001;20:655.
26. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 3.0. April 2005.
27. Elandt-Johnson RC, Johnson NL. Survival models and data analysis. New York: John Wiley & Sons, Inc.; 1980.
28. Cox DR, Oaks D. Analysis of survival data. London: Chapman and Hall; 1984.
29. Howlader N, Ries LA, Mariotto AB, et al. Improved estimates of cancer-Specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584-1598.
30. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010;116:5501-5506.
31. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-1999.
32. Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013;31:1984-1989.
33. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36(Suppl. 2):S24-S32.
34. Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 2011; 25: 181-191.
35. San-Miguel J, Harousseau JL, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761-2766.
36. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118: 4519-4529.
37. Harlan LC, Greene AL, Clegg LX, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005;23:9079-9088.
38. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
39. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-2152.
40. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-3560.
41. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
42. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209-1218.
43. Hulin C, Facon T, Rodon P, et al. efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
44. Fayers PM, Palumbo A, Hulin C, et al. T alidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-1247.
45. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448-455.